Squarepoint Ops LLC Caribou Biosciences, Inc. Transaction History

Squarepoint Ops LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.62 - $5.05 $164,146 - $511,691	-101,325 Reduced 59.63%	68,599 $112,000
Q1 2024 May 15, 2024	BUY	$4.82 - $8.26 $372,373 - $638,134	77,256 Added 83.37%	169,924 $873,000
Q4 2023 Feb 14, 2024	SELL	$3.58 - $6.25 $11,613 - $20,275	-3,244 Reduced 3.38%	92,668 $530,000
Q2 2023 Aug 14, 2023	BUY	$4.04 - $5.47 $98,309 - $133,106	24,334 Added 34.0%	95,912 $407,000
Q1 2023 May 15, 2023	SELL	$4.3 - $7.78 $257,914 - $466,644	-59,980 Reduced 45.59%	71,578 $380,000
Q4 2022 Feb 14, 2023	BUY	$5.57 - $11.01 $732,778 - $1.45 Million	131,558 New	131,558 $826,000
Q2 2022 Aug 15, 2022	BUY	$5.1 - $9.74 $204,872 - $391,265	40,171 New	40,171 $218,000
Q1 2022 May 16, 2022	SELL	$8.42 - $15.32 $645,738 - $1.17 Million	-76,691 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$14.59 - $23.26 $24,671 - $39,332	1,691 Added 2.25%	76,691 $1.16 Million
Q3 2021 Nov 15, 2021	BUY	$15.75 - $30.29 $1.18 Million - $2.27 Million	75,000 New	75,000 $1.79 Million

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $110M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.